77 related articles for article (PubMed ID: 28488840)
1. Bladder cancer and Th1 chemokines.
Paparo SR; Fallahi P
Clin Ter; 2017; 168(1):e59-e63. PubMed ID: 28488840
[TBL] [Abstract][Full Text] [Related]
2. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
[TBL] [Abstract][Full Text] [Related]
3. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
4. A novel expression of macrophage derived chemokine in human bladder cancer.
Yamada H; Luo Y; Matsumoto T; O'Donnell MA
J Urol; 2005 Mar; 173(3):990-5. PubMed ID: 15711363
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
[TBL] [Abstract][Full Text] [Related]
6. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.
Luo Y; Chen X; O'Donnell MA
Clin Exp Immunol; 2007 Feb; 147(2):370-8. PubMed ID: 17223980
[TBL] [Abstract][Full Text] [Related]
9. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
10. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy.
Agarwal A; Agrawal U; Verma S; Mohanty NK; Saxena S
Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):348-56. PubMed ID: 20105083
[TBL] [Abstract][Full Text] [Related]
11. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
13. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
14. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation.
Pavlovich CP; Kräling BM; Stewart RJ; Chen X; Bochner BH; Luster AD; Poppas DP; O'Donnell MA
J Urol; 2000 Jun; 163(6):2014-21. PubMed ID: 10799249
[TBL] [Abstract][Full Text] [Related]
15. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.
Saint F; Patard JJ; Maille P; Soyeux P; Hoznek A; Salomon L; De La Taille A; Abbou CC; Chopin DK
J Urol; 2001 Dec; 166(6):2142-7. PubMed ID: 11696723
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
Saint F; Patard JJ; Maille P; Soyeux P; Hoznek A; Salomon L; Abbou CC; Chopin DK
J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
[TBL] [Abstract][Full Text] [Related]
17. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
18. Intravesical immunotherapy for superficial bladder cancer.
Said MT; Abomelha MS; Orkubi SA
Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
[TBL] [Abstract][Full Text] [Related]
19. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells.
Chen X; O'DONNELL MA; Luo Y
Clin Exp Immunol; 2007 Jul; 149(1):178-85. PubMed ID: 17517055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]